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Bioluminescence imaging (BLI) enables real-time, noninvasive tracking of infection in vivo and longitudinal infection studies.
In this study, a bioluminescent Francisella tularensis strain, SCHU S4-lux, was used to develop an inhalational infection model
in BALB/c mice. Mice were infected intranasally, and the progression of infection was monitored in real time using BLI. A biolu-
minescent signal was detectable from 3 days postinfection (3 dpi), initially in the spleen and then in the liver and lymph nodes,
before finally becoming systemic. The level of bioluminescent signal correlated with bacterial numbers in vivo, enabling nonin-
vasive quantification of bacterial burdens in tissues. Treatment with levofloxacin (commencing at 4 dpi) significantly reduced
the BLI signal. Furthermore, BLI was able to distinguish noninvasively between different levofloxacin treatment regimens and to
identify sites of relapse following treatment cessation. These data demonstrate that BLI and SCHU S4-lux are suitable for the
study of F. tularensis pathogenesis and the evaluation of therapeutics for tularemia.
Francisella tularensis is a Gram-negative intracellular bacteriumand is the etiological agent of the disease tularemia. Tularemia
has a low infectious dose by the aerosol route (50% infectious dose
[ID50],10 CFU), causing a disabling illness without rapid treat-
ment, and is considered a potential biothreat agent. The preferred
treatments for tularemia are limited to a few antibiotics, including
fluoroquinolones (1, 2), tetracycline (3), streptomycin (4, 5), and
gentamicin (6, 7). The lack of a licensed vaccine, reported treat-
ment failures, even with preferred antibiotics (8), and a 2% mor-
tality rate despite treatment (5) necessitate the development and
evaluation of new therapies.
Conventional methods of assessing bacterial growth and dis-
semination in vivo require the infection of large cohorts of animals
and the culling of groups of animals at set time points throughout
a study. This strategy not only uses large numbers of animals but is
also labor-intensive and subject to tissue sampling bias. Noninva-
sive imaging techniques, such as bioluminescence imaging (BLI),
can report spatial and temporal aspects of infectious diseases in
vivo both longitudinally and in real time (9). BLI typically relies on
the detection of light produced by luciferase-catalyzed oxidation
reactions, which are encoded in the pathogen of interest, by use of
a sensitive charge-coupled device (CCD) camera (10). Pivotal ex-
periments by Contag et al. have demonstrated the usefulness of
BLI in the noninvasive study of bacterial pathogenesis and the
evaluation of antibiotic treatments for Salmonella enterica serovar
Typhimurium (11). Subsequently, bioluminescent reporters have
been introduced into other bacteria, includingMycobacterium tu-
berculosis (10, 12), Staphylococcus aureus (13, 14), Burkholderia
mallei (15), andYersinia pestis (16, 17). Further, BLI has been used
to evaluate vaccines (18), antibiotics (19–21), and supportive
therapies (22) for a range of pathogens. BLI is noninvasive, allow-
ing sequential imaging of the same animal and enabling the bac-
terial burden to be quantified without culling the animal, thus
reducing animal usage. Moreover, because the entire animal is
sampled, tissue sampling bias is reduced, and the identification of
different foci of infection is possible. This has the potential to
improve our understanding of disease progression and to aid in
the development of better treatments. A bioluminescent live vac-
cine strain (LVS) of F. tularensis has been constructed previously
(23). However, the plasmid encoding the luminescence was un-
stable in vivo, potentially leading to underestimation of the bacte-
rial load. This would be a considerable limitation in the use of this
strain to evaluate therapies. To date, no in vivo model has been
reported for bioluminescent F. tularensis SCHU S4.
Herewe describe the construction of a bioluminescent strain of
F. tularensis SCHUS4 anddemonstrate the suitability of this strain
for tracking disease progression. The value of BLI for the evalua-
tion of antibiotic treatment and the identification of sites of re-
lapse of disease is also demonstrated.
MATERIALS AND METHODS
Bacteria. Francisella tularensis subsp. tularensis strain SCHU S4 was cul-
tured on blood glucose cysteine agar (BCGA) plates or in modified cys-
teine partial hydrolysate (MCPH) broth supplemented with L-cysteine
and glucose. Electroporation was used to transform plasmid pEDL41
(containing luxCDABE) into SCHU S4 by methods described previously
(24), thereby constructing strain SCHU S4-lux. Bioluminescent strains
were cultured with hygromycin B (200 g ml1). All manipulations of F.
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tularensis SCHU S4 and SCHU S4-lux were performed in a class III mi-
crobiological safety cabinet.
Bacterial growth in vitro. Bacteria were grown at 37°C in 96-well
flat-bottom plates (200 l per well) with a starting optical density at 595
nm (OD595) of 0.02. Absorbance (expressed as OD595) was measured
every 30 min, using a plate reader capable of constant shaking, for 48 h.
Each strain was plated into 6 replicate wells. Wells containing MCPH
without bacteria served as medium controls.
Intracellular replication assay. Bacterial invasion and intracellular
survival were studied in J774A.1 murine macrophage-like cells. The cells
were seeded onto a 24-well tissue culture plate to give a concentration of
1 106 cells per well following overnight incubation in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Gibco Life Technologies) supplemented
with 1% L-glutamine and 10% fetal calf serum at 37°C.
One milliliter of Leibovitz’s L-15 medium (Gibco Life Technologies)
containing 106 CFU of either SCHU S4 or SCHU S4-luxwas added to cell
monolayers to achieve a multiplicity of infection (MOI) of 1. Each strain
was added to wells in triplicate for each time point. J774A.1 cells were
incubated with bacteria at 37°C for 1 h, after which the medium was
replacedwith L-15medium containing either 10gml1 gentamicin (for
the 1-h-postinfection [1-hpi] time point) or 2 g ml1 gentamicin (for
the 4- or 24-hpi time point). The cells were then reincubated at 37°C for 30
min, 4 h, or 24 h for the 1-, 4-, or 24-hpi time point, respectively. At these
time points, the L-15 medium was removed and the cells lysed with 1 ml
distilled water (dH2O). The cell lysates were serially diluted in phosphate-
buffered saline (PBS) and were plated onto BCGA plates in triplicate in
order to determine the intracellular bacterial load. The actual MOI was
determined by serially diluting the inoculum in sterile PBS and plating
onto BCGA plates. For SCHU S4-lux, cell lysates were plated onto BCGA
plates with or without hygromycin B in order to determine plasmid sta-
bility by comparing the bacterial numbers on selective and nonselective
agars.
Animals. All studies involving animals were performed in accordance
with the requirements of the Animal (Scientific Procedures) Act 1986.
Six- to 8-week-old female BALB/cmice were obtained fromCharles River
Laboratories and were randomly allocated to cages of fivemice each upon
arrival. The mice were implanted with microchips prior to arrival to en-
able the identification of individuals. The animals were housed within a
rigid-wall half-suit class III isolator with access to food and water ad libi-
tum and a 12-h light-dark cycle.
Following infection with F. tularensis, animals were handled under
ACDP (Advisory Committee for Dangerous Pathogens) containment
biosafety level III conditions for imaging studies (25). Mice were weighed
daily and were observed twice daily for clinical signs of disease. Upon
reaching predetermined humane endpoints, mice were culled by cervical
dislocation.
Bacterial challenge. Mice were infected by the intranasal route with
either F. tularensis SCHU S4 or SCHU S4-lux, both of which were pre-
pared by diluting frozen 10% sucrose stocks. For the bacterial challenge,
mice were briefly anesthetized using isoflurane within a bell jar and were
inoculatedwith approximately 103 CFU in a total volume of 50l PBS (25
l per naris). Serial dilution of the challenge dose and subsequent plating
onto BCGA plates in triplicate determined the actual CFU given.
Bioluminescent imaging. The IVIS Spectrum system (PerkinElmer)
measured the bioluminescent signal intensities during the imaging study
using an open emission filter with exposure times adjusted to collect be-
tween 600 and 60,000 counts. Two-dimensional images had the back-
ground signal subtracted, and image scaling was normalized by convert-
ing total counts to photons per second. Bioluminescent signal intensity is
represented by a pseudocolor scale ranging from red (most intense) to
violet (least intense). Signal intensity images were superimposed over
grayscale reference photographs for anatomical registration. Scales were
manually set to the same values for comparable images to normalize the
intensity of the bioluminescence across time points. Bioluminescence
within specific regions of individual animals was quantified using the
region-of-interest (ROI) tool in Living Image software, version 4.5
(PerkinElmer).
Mice were anesthetized for imaging with 40 mg ketamine (Vetalar;
Zoetis) kg of body weight1 and 0.75 mgmedetomidine (Domitor; Veto-
quinol) kg of body weight1, administered by the intraperitoneal route in
150 l sterile water. Mice were housed in a heated box to prevent hypo-
thermia during the anesthetic process. Anesthesia was reversed using 2.5
mg atipamezole (Antisedan; Zoetis) kg1, administered by the intraperi-
toneal route in 100 l sterile water. The mice remained in a heated box
until fully recovered. All mice were shaved (dorsum and abdomen/tho-
rax) under anesthesia prior to challenge in order to reduce signal absorp-
tion by the fur. Shaved mice had a recovery period of at least 24 h before
challenge.
Quantification of F. tularensis in vivo. The relationship between the
intensity of the bioluminescent signal and the bacterial burden in organs
was determined in order to allow noninvasive bacterial quantification in
vivo.
The in vivo bioluminescent signal was measured daily by imaging
groups of five mice under terminal anesthesia. Organs (lungs, liver, and
spleen) were aseptically removed from culled mice and were imaged ex
vivo. Groups of five mice were also inoculated with the parent strain,
SCHU S4, to provide a benchmark by which the fitness of the SCHU
S4-lux strain could be assessed.
The bacterial burden was determined by homogenizing organs in 1ml
PBS using a cell sieve and plating serial dilutions of tissue homogenates
onto BCGAplates. In vivo plasmid stability wasmeasured by plating tissue
homogenates frommice challenged with SCHU S4-lux onto BCGA plates
in triplicate with and without hygromycin B in order to calculate the ratio
of hygromycin-resistant to hygromycin-sensitive bacteria. Agar plates
were also imaged using the IVIS Spectrum system to confirm that the
bacteria isolated from the organs had retained the plasmid containing the
lux operon.
Antibiotic dosing schedule. Groups of 10 mice infected intranasally
with SCHU S4-lux were randomized to receive either (i) PBS, (ii) levo-
floxacin at 40 mg kg1, or (iii) levofloxacin at 5 mg kg1. All treatments
were administered intraperitoneally once daily for 7 days, starting at 4
days postinfection (4 dpi). Groups of animals (n 5) inoculated intrana-
sally with SCHU S4-lux and receiving no treatment or sham challenged
with PBSwere also included. Animalsweremonitored for 18 days after the
discontinuation of therapy in order to image any relapse.
Mice were imaged at regular intervals from 3 dpi until the end of the
study. To determine if repeated anesthesia affected antibiotic efficacy or
survival, groups of infectedmice receiving antibiotics only were included.
These animals were not imaged during the study, but organs were har-
vested and imaged postmortem (as above). At the end of the study (or
once mice had reached a predetermined humane endpoint), the mice
were terminally anesthetized, imaged, and culled. Organs (lungs, liver,
and spleen) from allmicewere aseptically removed andwere imaged prior
to processing for bacterial enumeration.
Statistical analysis.GraphPad Prism software, version 6, was used for
all statistical analysis and the production of all graphs. Differences in
survival data were analyzed using a log rank (Mantel-Cox) test. CFU data
were log transformed to fit the requirements for parametric analysis. Sta-
tistical differences between two groups were determined using an un-
paired t test. Statistical differences between three or more groups were
determined using one-way analysis of variance (ANOVA) followed by a
Bonferroni multiple-comparison test. To determine the relationship be-
tween CFU and bioluminescent signal intensity, data were log trans-
formed and a Pearson two-tailed correlation test was performed.R2 values
were calculated using linear regression analysis. Growth curves were com-
pared by log-transforming data and performing nonlinear regression
analysis. Two-way ANOVA with Sidak’s multiple-comparison test re-
vealed which time points were significantly different. Significance was
predetermined at a P value of0.05.
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RESULTS
SCHU S4-lux has an increased lag phase but is still virulent. In
vitro growth during the lag phase was significantly slower for
SCHU S4-lux than for the wild-type strain, SCHU S4, with a sig-
nificant increase in the time to an OD595 value of 0.02 (Fig. 1A).
However, the log phases for the two strains were similar, and no
significant difference inmean generation time was observed (data
not shown). Moreover, the plasmid was stably retained following
repeated subculturing in nonselective broth; 99% of colonies
retained the plasmid after 10 days (Fig. 1B). Mortality was 100%
for animals challenged with either SCHU S4 or SCHU S4-lux; the
median times to death were 4 and 5 days for the SCHU S4 and
SCHU S4-lux groups, respectively (Fig. 1D). Bacterial loads at the
time of death were equivalent for animals challenged with either
strain by the intranasal route (n  5) (Fig. 1C), indicating that
despite the difference in the lag phase of infection, the overall
ability of SCHUS4-lux to disseminate and replicate intracellularly
was not diminished. All animals in the PBS sham challenge group
survived until the end of the study and displayed no clinical signs
of infection (data not shown).
The bioluminescent signal is detectable with the onset of
clinical signs in an intranasal model of F. tularensis infection.
To determine if the bioluminescent signal was detectable in vivo,
groups of five mice were infected intranasally with approximately
103 CFU of SCHU S4-lux. At 3 dpi, the mice displayed no clinical
signs of infection, and no bioluminescent signal was detected (Fig.
2). However, bioluminescent signals were detected from the ex-
planted lungs of 3 out of 5 mice (Fig. 3). By 4 dpi, mice displayed
mild clinical signs—namely, various degrees of fur ruffling—and
bioluminescent signals were detected in the spleens (Fig. 2); the
anatomical location of the signal was confirmed by imaging the
explanted organs (Fig. 3). During the primary infection, the bio-
luminescent signal spread from the spleen to the lymph nodes and
liver before becoming systemic, with signal detectable in the lungs
by 5 dpi (Fig. 2). The increase in bacterial loads seen between 3 dpi
and 5 dpi occurred more rapidly in the spleens (4.3 log units) and
livers (3.9 log units) than in the lungs (1.6 log units) (Fig. 4). No
bioluminescent signal was detected in mice challenged with the
parent strain, SCHUS4, or with PBS at any time point (images not
shown).
The level of bioluminescent signal (total flux) correlateswith
bacterial numbers in vivo.The relationship between the bacterial
burden and the bioluminescent signal was established in order to
determinewhether BLI would allow noninvasive quantification of
bacterial loads. The relationship between signal depth and signal
attenuation by tissue required detection limits to be determined
separately for the lungs, liver, and spleen.
There was a strong positive correlation between in vivo biolu-
minescence (expressed as total flux, in photons per second) and
bacterial burdens in the lungs, livers, and spleens (Fig. 5). The
detection limit was calculated using linear regression analysis,
with the detection threshold set at twice the average background
signal measured in the wild-type group for each organ (Fig. 5).
The calculated limits of detection were 6.46, 4.85, and 5.51 log10
CFU for the lungs, liver, and spleen, respectively, based on groups
of 15 animals.
Noninvasive imaging is a sensitive measure of treatment ef-
ficacy at early time points. The utility of BLI for distinguishing
FIG 1 Lux-marked SCHUS4 is stably replicated and virulent, but the lag phase of growth and the time to death are longer than those for SCHUS4. To determine
if the lux reporter impacted SCHU S4 fitness, SCHU S4-lux was compared to SCHU S4 with regard to in vitro growth (3 separate experiments with 6 technical
replicates per experiment) (A), bacterial burdens in organs (n, 5 animals per group) (C), and survival in a BALB/cmousemodel (n, 5 animals per group) (D). The
asterisk indicates a P value of 0.05. (B) In vitro plasmid stability and bioluminescencewere alsomeasured in the absence of antibiotic selective pressure (3 separate
experiments with 3 technical replicates per experiment). The data shown represent mean values standard deviations.
BLI To Study Inhalational Tularemia and Treatment
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between different treatment regimens was assessed in a subopti-
mal antibiotic model. Groups of mice (n, 5 to 10) were infected
intranasally with approximately 103 CFU of SCHU S4-lux. Levo-
floxacin (at 5 mg kg1 or 40 mg kg1) or PBS was administered
intraperitoneally once daily for 7 days, at the onset of a biolumi-
nescent signal at 4 dpi (Fig. 6).
At 5 dpi, the bioluminescent signal was diminished in both
groups of mice receiving levofloxacin (n, 10 per group) (Fig. 6).
The bioluminescent signal was below the limit of detection by 6
and 7 dpi for the groups dosed with 40 mg kg1 and 5 mg kg1
levofloxacin, respectively. Animals in the 5-mg kg1 levofloxacin
group had significantly higher total flux values in the thoracic and
abdominal regions than animals in the 40-mg kg1 levofloxacin
group at 5 and 6 dpi (Fig. 7). No significant differences in other
noninvasive parameters, including weight loss and clinical scores,
were foundbetween the two levofloxacin-dosed groups during the
same period (Fig. 7). In SCHU S4-lux-infected animals receiving
either PBS treatment or no treatment, the bioluminescent signal
increased over the duration of the experiment until the animals
FIG 2 In vivo imaging of BALB/c mice infected with SCHU S4-lux by the intranasal route. On days 3 to 5 postinfection, mice were terminally anesthetized and
were imaged in ventral and dorsal alignments. The images shown are representative of groups of 5 mice at each time point. The intensity of photon emission is
represented by pseudocolor images. The scale from blue to red represents low to high radiance efficiency (expressed as photons per second per square centimeter
per steradian), respectively.
FIG 3 In vivo bioluminescent signal quantification in BALB/c mice infected
with SCHU S4-lux by the intranasal route. On days 3 to 5 postinfection, mice
were terminally anesthetized, imaged, and culled following image acquisition,
and organs (lungs, liver, and spleen)were aseptically removed and individually
imaged. The images shown are representative of groups of 5 mice at each time
point. The intensity of photon emission is represented by pseudocolor images.
The scale fromblue to red represents low to high radiance efficiency (expressed
as photons per second per square centimeter per steradian), respectively.
FIG 4 SCHU S4-lux growth is slower in the lungs than in the spleen and liver.
Groups of mice (n 5) infected with 103 CFU of SCHU S4-lux were culled at
3, 4, and 5 dpi. The bacterial loads in the lung, liver, and spleen were deter-
mined by plating organ homogenates onto BCGA plates. Bacterial numbers
are reported as total CFU for each organ. Data represent mean values stan-
dard deviations.
Hall et al.
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reached humane endpoints (Fig. 6). PBS treatment had no impact
on the level of the bioluminescent signal; similar total flux values
were observed for the PBS-treated and untreated groups (Fig. 6).
Noninvasive imaging identifies sites of relapse.Animals were
monitored and imaged for 18 days after the completion of therapy
in order to determine sites of relapse of infection. No biolumines-
cent signal was detected in animals treated with 40 mg kg1 levo-
floxacin (n 10). While bacteria were detected in spleen homog-
enates from these animals, no bacteria were detected in 22% and
33% of lung and liver samples, respectively (Fig. 8). However, 1 of
10 animals in the group dosed with 5 mg kg1 levofloxacin
showed clinical signs of relapse that subsequently resulted in a
lethal infection. In this animal, the bioluminescent signal was be-
low the limit of detection at the completion of antibiotic therapy,
but by 14 dpi (3 days after the end of therapy), bioluminescence
was evident in the intestinal region (Fig. 9). The bioluminescent
signal continued to increase and spread from the intestinal region
to the lungs and lymph nodes. By day 16 postinfection, the animal
had succumbed to infection; the strongest bioluminescent signal
was detected in the lung postmortem (Fig. 8). Strong foci of signal
were detected ex vivo in the colon region of the intestines, presum-
ably in Peyer’s patches (Fig. 10). Foci of bioluminescence in the
intestines were also observed postmortem in animals in the non-
imaged group dosed with 5 mg kg1 levofloxacin.
DISCUSSION
This study used a plasmid-based approach to generate a biolumi-
nescent strain of SCHU S4 suitable for real-time visualization and
quantification of pulmonary tularemia using BLI. The incorpora-
tion of luciferase-encoding plasmids into bacteria is a common
approach for the development of bioluminescent reporter strains
(26). Chromosomally integrated luciferases are often preferred
(27), because they are more stable than plasmid-based reporters,
although sensitivity is generally lower (17, 28). It is recognized that
plasmid-based reporters may be unstable in vivo in the absence of
antibiotic selection (23, 29, 30). However, this study demonstrates
that pEDL41 is stably maintained in the absence of antibiotic se-
lection, both in vitro and in vivo. This plasmid is derived from the
pFN10 family of Francisella shuttle vectors carrying orf4 and orf5
(31). Based on the homology of orf5with the axe (32) and phd (33)
antitoxins, orf4 and orf5 are thought to encode components of a
plasmid addiction system which likely improve plasmid retention
in vivo and in vitro (13). In this study, the concentration of bacteria
required to generate a detectable signal in vivowas relatively high,
which may have limited the detection of bacteria very early in
infection. However, this did not present a problem when imaging
was performed at later time points in the infection, and our
method allowed for treatment failure and relapse of infection to be
visualized. Approaches to improving sensitivity could include the
use of other reporters, such as red-shifted firefly luciferase, which
have a lower metabolic burden (10, 34).
A significant difference in time to death was observed between
mice infected with SCHU S4-lux and those infected with the pa-
rental wild-type strain, SCHU S4. However, there was no differ-
ence in mortality between these groups of animals. These in vivo
findings might reflect the longer lag growth phase seen in vitro for
SCHU S4-lux than for SCHU S4 and the similarity of the growth
rates and cell densities of the strains in the exponential- and sta-
tionary-growth phases. This altered growth profile of SCHU S4-
lux could be attributed to the early loss of the plasmid in the
absence of antibiotic selective pressure. However, plasmid stabil-
ity was calculated as 99% in bacteria repeatedly subcultured in
nonselective broth as well as in bacteria isolated from organs, sug-
gesting that the extended lag phase did not simply reflect plasmid
loss.
Studies using S. Typhimurium have shown increased global
gene expression during the lag phase, with upregulation of nucle-
otide metabolism and fatty acid biosynthesis (35). Therefore, it is
hypothesized that the substrate and energy requirements of pro-
ducing a bioluminescent signal would compete with the energy
requirements for growth and would thus compromise the adap-
FIG 5 The intensity of the bioluminescent signal strongly correlates with
bacterial loads in organs. Shown are the correlations between the levels of the
bioluminescent signal detected and the numbers of bacteria in lungs (A), livers
(B), and spleens (C) removed from mice infected with 103 CFU of SCHU
S4-lux (n 15). The bioluminescent signal (expressed as total flux) was mea-
sured for regions of interest corresponding to specific anatomical areas. The
limits of detection (LOD) were calculated for each organ using linear regres-
sion analysis with the detection threshold set at twice the average background
signal. Data points represent individual animals.
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tation of bacterial cells during the lag phase. A number of pub-
lished studies have documented the level of attenuation that
luxCDABE expression causes in bacteria. Impaired growth in vitro
as a function of light intensity has been reported for some biolu-
minescent Vibrio species (36) and for Streptococcus pyogenes (29).
In addition, a competitive disadvantage at the site of infection in
vivo has been reported for S. pyogenes (29) and Citrobacter roden-
tium (37).
This study builds on previously reported BLI studies using a
bioluminescent strain of F. tularensis LVS in mice (23, 38) and
highlights the differences in pathogenesis between strains of dif-
fering virulence. Following an intranasal challenge with LVS-lux,
bioluminescencewas detected first in the lungs at 1 dpi and then in
the lymph nodes, spleen, and liver by 3 or 4 dpi (23, 38). However,
in our study, the bioluminescent signal was initially detected in the
spleen at 4 dpi following an intranasal infectionwith 103CFU. The
bioluminescent signal could then be detected in the lymph nodes
and liver before becoming systemic; the signal was not detected in
the lungs until 5 dpi. The differences in the location and spread of
signal between LVS-lux and SCHU S4-lux could be due to the
differences in the challenge doses used. Infecting with a higher
dose (5  105 to 1  106 CFU) of LVS-lux may have enabled
earlier detection in the lungs than was observed after challenge
with 103 CFU of SCHU S4-lux.
FIG 6 Noninvasive optical imaging can be used to distinguish visually between different antibiotic regimens. Mice infected with 103 CFU SCHU S4-lux were
treated with either PBS, 5 mg kg1 levofloxacin, or 40mg kg1 levofloxacin administered by the intraperitoneal route and were imaged before, during, and after
treatment. Representative images are shown for one mouse per group (n, 10 mice each in the PBS and levofloxacin treatment groups). Additionally, control
groups of mice receiving either an SCHU S4-lux challenge or a PBS sham challenge but no further treatment were included (n, 5 mice each in the no-treatment
and sham challenge groups). Image scaling was normalized by converting total counts to photons per second. The intensity of photon emission is represented by
pseudocolor images. The scale from blue to red represents low to high radiance efficiency (expressed as photons per second per square centimeter per steradian),
respectively.
Hall et al.
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Early detection of bioluminescence in the lung may be hin-
dered by a number of factors. Differences in the ability to image
infection in different organsmay reflect the anatomical location of
the organwithin the animal, since signal intensity is inversely pro-
portional to signal depth (39). Therefore, the limit of detection in
the lung was approximately 1 to 1.5 log units higher than the limit
of detection in the spleen or liver. Additionally, the proximity of
the lungs to the heart could further reduce signal intensity, since
oxy- and deoxyhemoglobin absorb light wavelengths between
	400 and 600 nm (40), and attenuation of the bioluminescent
signal emitted frombacteria located in the lungs has been reported
for other pathogens (41).
FIG 7 Mice receiving different doses of levofloxacin can be distinguished by the
bioluminescent signal, but not by weight loss, early in antibiotic treatment. (A)
Total flux fromthe thoracic andabdominal regions (normalizedby area, in square
centimeters)wasmeasuredandplottedover time for animals receivingeither5mg
kg1 or 40mg kg1 levofloxacin. The dashed horizontal line indicates the limit of
detection (LOD). (B) Animal weights were recorded daily andwere plotted as the
percentage of weight change relative to prechallenge weights. The data shown
representmean values standard deviations (n, 10mice per group). Double and
triple asterisks indicate P values of0.01 and0.001, respectively.
FIG 8 Bacterial clearance is not achieved following delayed antibiotic treat-
ment. Groups ofmice (n 10) infected with SCHU S4-lux received either 5 or
40 mg kg1 of levofloxacin by intraperitoneal injection. Bacterial loads for the
lungs, liver, and spleen were determined by plating organ homogenates onto
BCGA plates. The limit of detection (LOD) is indicated. Bacterial numbers are
reported as the total CFU for each organ. Individual data points are plotted,
and the central line for each group represents the mean value.
FIG 9 Noninvasive imaging enables the visualization of antibiotic efficacy.
Mice were imaged before the start of antibiotic treatment (days 3 and 4),
during treatment, and up to 18 days after the cessation of treatment. Shown is
the infection course of one mouse in the suboptimal antibiotic treatment
group (5 mg kg1 levofloxacin). The bioluminescent signal decreases below
the limit of detection following antibiotic treatment. Treatment was termi-
nated on day 11, and a bioluminescent signal was detected in the intestinal
region by day 15, indicating a relapse that progresses to a lethal infection, with
a strong signal in the lungs.
FIG 10 Bioluminescence imaging can assist in identifying sites of infection.
(A) Bioluminescence was detected in the intestines of all relapsing mice.
Shown are representative images from one of five relapsing mice. (B) Discrete
foci of bioluminescent signal were observed in regions that did not otherwise
show any gross pathology and that are presumed to be Peyer’s patches.
BLI To Study Inhalational Tularemia and Treatment
December 2016 Volume 60 Number 12 aac.asm.org 7Antimicrobial Agents and Chemotherapy
C
O
L
O
R
C
O
L
O
R
AQ: F
C
O
L
O
R
AQ: G
C
O
L
O
R
zac01216/zac5743d16z xppws S1 10/18/16 23:43 4/C Fig: 1,2,3,4,5,6,7,8,9,10 ArtID: 01586-16 NLM: research-article CE: jmm
The progression of infection visualized using BLI correlated
with the bacterial load data from the organs; more-rapid increases
in CFU counts were seen in the spleen (4.3 log units) and liver (3.9
log units) than in the lungs (1.6 log units) between 3 and 5 dpi. The
kinetics of bacterial growth in different organs observed in this
study are in agreement with those in previous studies, where bac-
teria grew more slowly in the lungs than in the liver and spleen
following an intranasal challenge (42–44). Overall, these BLI data
support the idea that it is widespread sepsis and systemic inflam-
mation, rather than the primary pneumonia, that contribute to
mortality (45–47).
Relapse following the withdrawal of antibiotics has been re-
ported clinically (4, 5) and in experimental animals infected with
F. tularensis (43, 48–50). In this study, the initiation of treatment
was delayed until 4 dpi, and following the cessation of antibiotics,
relapse was observed in 30%of the animals treatedwith 5mg kg1
levofloxacin. The relapse rate in this study is broadly similar to
that reported previously (43). BLI enabled the tracking of infec-
tion during relapse and revealed that a bioluminescent signal
could be detected in the gastrointestinal tract 3 days after the ces-
sation of antibiotic therapy, before the detection of a signal in the
thoracic cavity. After amouse succumbed to the infection at 16 dpi
(5 days following the termination of therapy), a bioluminescent
signal was localized to discrete foci of infection within the intes-
tines associated with lymphoid tissue, presumed to be Peyer’s
patches. It is possible that this represents a site of persistence from
which the infection can be reestablished, since persistence in and
dissemination from the gastrointestinal tract, specifically the
Peyer’s patches, has beenwidely reported for other pathogenswith
an intestinal tropism, including Bacillus anthracis (41), Yersinia
pseudotuberculosis (51), Mycobacterium avium subsp. paratuber-
culosis (52), and Listeria monocytogenes (53). In another study,
Ojeda et al. reported early trafficking of Francisella novicida to the
gastrointestinal tract following infection by both the intranasal
and intratracheal routes, with viable bacteria detected in the Pey-
er’s patches (54). Following subcutaneous infection of field voles
with F. tularensis subsp. holarctica, both intracellular and extracel-
lular bacteria were detected in Peyer’s patches as well as in intes-
tinal epithelial cells (55). Thus, there is a growing body of data
suggesting that Francisella is able to colonize Peyer’s patches and
that, as with other pathogens, persistence in and dissemination
from the gastrointestinal tract may contribute to pathogenesis.
The reemergence of a bioluminescent signal in the lungs of
SCHU S4-lux-infected mice could indicate bacterial trafficking
from the gut to the lungs. Pneumonia resulting from bacterial
translocation via the gut-lung axis has been reported for other
pathogens, including L. monocytogenes (53) and Streptococcus
pneumoniae (56). Additionally, the gastrointestinal microbiota
plays a role in regulating bacterial translocation, and treatments
that disrupt microbiota dynamics, such as antibiotics, may in-
crease bacterial translocation (57). Further work is needed to de-
termine the spatiotemporal population dynamics during relapse
of infection with F. tularensis SCHU S4 and to determine whether
different subpopulations of bacteria are responsible for the re-
emergence of infection in different organs, as noted previously for
persistent Salmonella infections (58, 59).
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